The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling

• Main Authors: Rameseder, J. (Author), Zhang, Y. (Author), Ottina, Kathleen (Contributor), Lim, D. (Author), Choi, Y. (Author), Gray, Nathanael S. (Author), Yaffe, M. B. (Author), Marto, Jarrod A. (Author), Hsu, Peggy P. (Contributor), Kang, Seong A. (Contributor), Peterson, Timothy R. (Contributor), Sabatini, David M. (Contributor)
• Other Authors: Massachusetts Institute of Technology. Department of Biology (Contributor)
• Format: Article
• Language: English
• Published: American Association for the Advancement of Science (AAAS), 2013-09-30T19:34:44Z.
• Subjects: Article
• Online Access: Get fulltext

September 21 Author Manuscript
The mammalian target of rapamycin (mTOR) protein kinase is a master growth promoter that nucleates two complexes, mTORC1 and mTORC2. Despite the diverse processes controlled by mTOR, few substrates are known. We defined the mTOR-regulated phosphoproteome by quantitative mass spectrometry and characterized the primary sequence motif specificity of mTOR using positional scanning peptide libraries. We found that the phosphorylation response to insulin is largely mTOR dependent and that mTOR exhibits a unique preference for proline, hydrophobic, and aromatic residues at the +1 position. The adaptor protein Grb10 was identified as an mTORC1 substrate that mediates the inhibition of phosphoinositide 3-kinase typical of cells lacking tuberous sclerosis complex 2 (TSC2), a tumor suppressor and negative regulator of mTORC1. Our work clarifies how mTORC1 inhibits growth factor signaling and opens new areas of investigation in mTOR biology.
National Institutes of Health (U.S.) (Grant CA103866)
National Institutes of Health (U.S.) (Grant AI47389)
United States. Department of Defense (W81XWH-07-0448)
W. M. Keck Foundation
LAM Foundation
American Cancer Society
Howard Hughes Medical Institute (Investigator)